People with implanted heart pumps may have higher suicide risk

By American Heart Association News

Jolygon/iStock, Getty Images
(Jolygon/iStock, Getty Images)

People with a left ventricular assist device, a mechanical pump that helps the heart, might face a higher suicide risk, new research suggests.

LVADs are used to treat advanced heart failure, where a weakened heart can't pump enough blood to meet the body's needs. The condition is advanced when medicines and lifestyle adaptations are no longer adequate treatments. In the U.S., about 2,400 people received an LVAD in 2014, the latest year for which figures are available.

The new France-based research included 494 patients of which 87% were men. They had received an LVAD between 2006 and 2016 across 19 medical centers. Among the study subjects, 10 of them, or 2%, attempted or died of suicide during a year and a half of follow-up. As a point of reference, the authors noted the suicide attempt rate for people with chronic diseases overall is 0.06% in France.

Eight of the study participants died of suicide. Most of the cases involved cutting an LVAD cable or removing the batteries.

"LVAD complications are mostly infection, strokes, bleeding. But psychological distress and psychiatric symptoms such as depression, anxiety, sleep disorders are also very important to detect and manage," said lead study author Dr. Vincent Galand, a cardiologist at the Centre Hospitalier Universitaire in Rennes, France. Only two of the people who tried or died of suicide had a history of psychiatric illness, the study found.

Having an LVAD, plus medical complications and recurrent hospitalizations, is daunting, Galand said.

"Patients who return to a full-time job remain rare, and many may still feel handicapped in their relationship and daily life," he said. They rely on the LVAD and cardiac specialists for survival, and often are dependent on caregivers. "This dependence can be perceived as having a lack of control over one's life and can lead to anger or hopelessness."

The research appeared Tuesday in the American Heart Association journal Circulation.

Dr. Mark Slaughter, professor and chair of the department of cardiovascular and thoracic surgery at the University of Louisville School of Medicine in Kentucky, said the study reinforces experts' understanding that LVAD recipients need ongoing physical and emotional support. Although the research was from Europe, he believes the findings are relevant in the U.S.

Among more than 6 million Americans with heart failure, about 10% have advanced disease. LVADs are life-sustaining for these people as many wait a year or more for a heart transplant. The devices also are commonly used as "destination therapy," a final treatment option for those who are not transplant candidates. The proportion of LVADs implanted as destination therapy grew from 2% in 2008 to 49% in 2017.

In the study, 80% of the suicide group received the devices as destination therapy, versus one-third of the other patients. Galand said these patients might feel particularly burdened because of their transplant ineligibility and lack of other treatment options.

"This study is a plea to change our long-term follow-up and systematically include an LVAD nurse coordinator who daily supports LVAD recipients, and who represents a link between patients' families and medical teams," he said.

Other solutions could include a psychiatric exam before surgery when possible, and depression and anxiety screening during cardiac rehabilitation, just before patients go home.

In the U.S., LVAD recipients and families receive emotional and medical support from palliative care teams. Ventricular assist device coordinators help manage and support patients after hospital discharge, Slaughter said. Many hospitals see these patients weekly for one to two months during recovery.

"VAD coordinators as well as the physicians are keenly aware of these possible issues and provide support or additional treatment when indicated."

But even before an LVAD is implanted, heart failure poses psychological challenges, he said. "Many patients aren't aware that ultimately they will either need a heart transplant or LVAD to survive. It frequently is a shock to them and requires time and education so they understand the limitations of the therapy as well as its benefits."

The National Suicide Prevention Lifeline is available at 800-273-8255.

If you have questions or comments about this story, please email editor@heart.org.


American Heart Association News Stories

American Heart Association News covers heart disease, stroke and related health issues. Not all views expressed in American Heart Association News stories reflect the official position of the American Heart Association.

Copyright is owned or held by the American Heart Association, Inc., and all rights are reserved. Permission is granted, at no cost and without need for further request, for individuals, media outlets, and non-commercial education and awareness efforts to link to, quote, excerpt or reprint from these stories in any medium as long as no text is altered and proper attribution is made to American Heart Association News.

Other uses, including educational products or services sold for profit, must comply with the American Heart Association’s Copyright Permission Guidelines. See full terms of use. These stories may not be used to promote or endorse a commercial product or service.

HEALTH CARE DISCLAIMER: This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. If you are in the United States and experiencing a medical emergency, call 911 or call for emergency medical help immediately.